



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	121.33
Trade Time:	4:15 PM ET Oct 20, 2017
Change:	-14.63 (10.761%)
Day Range	120.80 - 124.54
52-Week Range	96.93 - 147.17
Volume	27,741,326

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID[®], VIDAZA[®], THALOMID[®], POMALYST[®]/IMNOVID[®], ABRAXANE[®], OTEZLA[®], ISTODAX[®] and IDHIFA[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Oct 19, 2017

[Celgene Provides Update on GED-0301 \(mongersen\) Inflammatory Bowel Disease Program](#)

Oct 19, 2017

[Phase III Efficacy and Safety Data for Oral Olanizimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting](#)

Oct 16, 2017

[Results from Phase 2 Studies of Oral Olanizimod in Crohn's Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG2017](#)

Oct 2, 2017

[Celgene Corporation to Announce Third Quarter 2017 Results on October 26, 2017; Will Host an Investor Webcast Event from the MSParis2017-7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017](#)

Sep 8, 2017

[Data Presented at ESMO 2017 Further Evaluate Role of ABRAXANE[®] for Patients with Historically Challenging Cancers](#)

Upcoming Events [\[View all \]](#)

Oct 26, 2017 9:00 AM ET

[Celgene Corporation Q3 2017 Celgene Corp. Earnings Conference Call](#)

Oct 28, 2017 12:00 PM ET

[Celgene Event at ECTRIMS](#)

Financials [\[View all \]](#)

Feb 10, 2017

[Annual Report \(10-K\)](#)

Apr 27, 2017

[Proxy Statement \(DEF 14A\)](#)

Jul 27, 2017

[Quarterly Report \(10-Q\)](#)

Apr 27, 2017

[Quarterly Report \(10-Q\)](#)

Oct 27, 2016

[Quarterly Report \(10-Q\)](#)